View Older Stories
-
Deutsche Bank Downgrades Bio-Techne Corp. (TECH) to Hold
-
William Blair Downgrades Bio-Techne Corp. (TECH) to Market Perform
-
TD Cowen Highlights Bio-Techne Corp. (TECH) as a Best Smidcap Idea
-
Activist Ananym builds stake in Bio-Techne, urges strategic review - Bloomberg
-
Piper Sandler Starts Bio-Techne Corp. (TECH) at Neutral
-
Bio-Techne and Refeyn launch integrated workflow for antibody analysis
-
RBC Capital Assumes Bio-Techne Corp. (TECH) at Outperform
-
Bio-Techne (TECH) Misses Q3 EPS by 1c
-
Bio-Techne expands COMET spatial biology platform with new tools
-
Evercore: ' Latest Survey Work Positions 2026 As Better Year For Biopharma Spending'
-
TD Cowen: 'MSFT's AI-Powered Spatial Product Weakens Spatial Exposed Stocks'
-
TD Cowen on Bio-Techne Corp. (TECH): 'Sell-Off Looks Overdone, We'd Be Buyers on Today's Weakness'
-
Bio-Techne Corp. (TECH) PT Raised to $68 at Argus
-
Bio-Techne names Steve Crouse president of diagnostics segment
-
Bio-Techne Corp. (TECH) PT Raised to $65 at Stifel
-
Bio-Techne (TECH) Tops Q2 EPS by 3c
-
Benchmark Reiterates Buy Rating on Bio-Techne Corp. (TECH)
-
Bio-Techne launches synthetic hydrogel for 3D cell culture research
-
Bio-Techne launches ultra-sensitive assays for neurological biomarkers
-
Bio-Techne partners with Wyss Center to develop 3D tissue analysis technology
-
Bio-Techne launches enhanced Leo protein analysis system
-
Bio-Techne licenses AI-designed proteins from Monod Bio
-
Bio-Techne launches ProximityScope assay for protein interaction research
-
Bio-Techne expands Oxford Nanopore partnership through 2032
-
Bio-Techne showcases spatial biology tools at histology convention
-
This life science company is raising eyebrows amid delayed filing
-
Citi Upgrades Bio-Techne Corp. (TECH) to Buy
-
Bio-Techne (TECH) Tops Q4 EPS by 3c
-
Bio-Techne divests Exosome Diagnostics unit to Mdxhealth for $5 million
-
Spear Bio partners with Bio-Techne to distribute immunoassay technology
-
Bio-Techne technology used in FDA-approved gene therapy ZEVASKYN
-
Bio-Techne Corp. (TECH) PT Lowered to $75 at Scotiabank
-
TD Cowen Starts Bio-Techne Corp. (TECH) at Buy
-
Stifel Reiterates Hold Rating on Bio-Techne Corp. (TECH)
-
Maravai LifeSciences (MRVI) on watch on vague chatter following CEO change
-
Benchmark Reiterates Buy Rating on Bio-Techne Corp. (TECH)
-
Bio-Techne Corp. (TECH) PT Lowered to $65 at Argus
-
Wells Fargo Starts Bio-Techne Corp. (TECH) at Overweight
-
Citi names 3 stocks as its new top picks in the Life Science sector
-
Bio-Techne (TECH) Tops Q3 EPS by 5c
-
KeyBanc Downgrades Bio-Techne Corp. (TECH) to Sector Weight
-
Evercore ISI Starts Bio-Techne Corp. (TECH) at Outperform
-
Bio-Techne (TECH) Begins Shipping Leo
-
Bio-Techne (TECH) Announces Release of GMP TcBuster Non-Viral Genome Engineering System
-
Bio-Techne Corp. (TECH) PT Raised to $80 at RBC Capital as '9% Organic Growth Drives Beat'
-
Bio-Techne Corp. (TECH) PT Raised to $90 at KeyBanc Following 'Strong Results'
-
Bio-Techne Corp. (TECH) PT Raised to $90 at Scotiabank
-
Bio-Techne (TECH) Tops Q2 EPS by 3c
-
Bio-Techne (TECH) Appoints Amy E. Herr to its Board
-
Bio-Techne (TECH) Successful On Second Claim Of Reverse Engineering By Miltenyi Biotec

